A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer

1. Wehler, T.
2. Thomas, M.
3. Schumann, C.
4. Bosch-Barrera, J.
5. Viñolas Segarra, N.
6. Dickgreber, N.J.
7. Dalhoff, K.
8. Sebastian, M.
9. Corral Jaime, J.
10. Alonso, M.
11. Hynes, S.M.
12. Lin, J.
13. Hurt, K.
14. Bence Lin, A.
15. Calvo, E.
16. Paz-Ares, L.